Brief: Poxel Initiates Phase 2 NASH Trial For PXL065

Poxel SA

02/09/2020 07:04

Sept 2 (Reuters) - Poxel SA  POXEL.PA :
    * POXEL INITIATES PHASE 2 NASH TRIAL FOR PXL065 (DESTINY 1)
IN
BIOPSY-PROVEN PATIENTS
    * PHASE 2 TRIAL WILL INCLUDE APPROXIMATELY 120 NONCIRRHOTIC
BIOPSY-PROVEN NASH PATIENTS AND IS DESIGNED TO IDENTIFY OPTIMAL
DOSE OR DOSES FOR PHASE 3 REGISTRATION TRIAL
    * PRIMARY ENDPOINT OF DESTINY 1 WILL MEASURE RELATIVE CHANGE
IN
PERCENTAGE OF LIVER FAT AS MEASURED BY MRI-PDFF

Source text for Eikon:  ID:nBw3PCM24a 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))